Vetoryl double divisible flavoured tablet range now available

Dechra has launched its double divisible, flavoured tablets for the treatment of Cushing’s syndrome, Vetoryl Flavoured Tablets for Dogs.

The new Vetoryl Flavoured Tablets for Dogs are hydrolysed chicken flavoured tablets featuring SmartTabÔ technology which allows the tablets to be easily divided into halves or quarters to ensure accurate dosing. They are available as 20mg, 30mg and 60mg tablets alongside the Vetoryl 5mg, 10mg, 30mg, 60mg and 120mg hard capsules and come in packs of 30 tablets.

Vetoryl contains trilostane as its active ingredient and is licensed for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s syndrome) in dogs. It has been on the market for 20 years with over 300 million capsules sold since its launch and is supported by a combination of Dechra’s extensive technical endocrinology experience and its comprehensive support initiatives.

Thomas Johnson, Vetoryl brand manager at Dechra, comments: “Vetoryl Flavoured Tablets for Dogs are a welcome addition to our Vetoryl product range and can aid compliance, while providing both vets and dog owners with additional dosing flexibility.”

For further information please contact your local Dechra territory sales manager or visit www.dechra.co.uk/products/dog/prescription/vetoryl.

For the latest updates and in-depth insights into the world of Animal Health, including breakthrough treatments, industry trends, and regulatory news, contact Poppy Hodge today!